Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 6,111

Document Document Title
WO2003084922A8
The invention relates to acyl-4-carboxyphenylurea derivatives, the physiologically-acceptable salts, physiologically-functional derivatives thereof and compounds of formula (I), where the groups have the given meanings, the physiological...  
WO2004087646A3
The invention relates to the compounds of formula (I), wherein W represents N, CR<3>, or a sp<2 >hybridized C atom, E, together with W, represents a 3- to 7-membered saturated carbocylic or heterocyclic ring having 0 to 3 N atoms, 0 to 2...  
WO/2005/000794A1
Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor m...  
WO/2005/000803A2
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO2004002940A8  
WO2003095438A9
Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.  
WO/2004/110989A1
This invention relates to novel N-hydroxy-7-(arylamino)heptanamide derivative compounds including salts, carbonates and O-acylated derivatives thereof, pharmaceutical compositions containing such compounds, and the use of those compounds...  
WO2003093250A3
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...  
WO2004078144A3
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...  
WO/2004/106291A1
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.  
WO/2004/106292A1
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as anti-proliferative agent in the attenuation, inhibition, or prevention of non-cancerous cellular proliferation. These compounds are also...  
WO2004026815A3
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...  
WO/2004/103281A2
One aspect of the invention relates to antagonists of mammalian vanilloid receptors. Another aspect of the invention relates to a method of modulating the activity of a vanilloid receptor in a mammal, comprising administering a compound ...  
WO/2004/101752A2
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthriti...  
WO2004007407A3
The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous na...  
WO2004084842A3
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., ca...  
WO/2004/098512A2
The present application describes modulators of MCP 1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2004/096771A1
Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein one of Ar1 and Ar2 is phenyl linked in a 1,4-relationship, and the other is phenyl linked in a 1,4-relationship or a 6 membered heteroaryl ring...  
WO/2004/096758A1
The invention relates to a process for the preparation of a urea and formaldehyde-containing aqueous solution (UFC), wherein the molar ratio between urea and formaldehyde (U/F) in the solution is between 0.5 and 0.001, wherein the UFC is...  
WO2003087044A3  
WO2003077847A3  
WO/2004/089885A1
The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.  
WO/2004/089874A1
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.  
WO/2004/089296A2
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.  
WO/2004/087646A2
The invention relates to the compounds of formula (I), wherein W represents N, CR3, or a sp2 hybridized C atom, E, together with W, represents a 3- to 7-membered saturated carbocylic or heterocyclic ring having 0 to 3 N atoms, 0 to 2 O a...  
WO/2004/087696A1
The invention relates to novel compounds of formula (I), where R, R1, R2 and R3 have the meanings given in claim 1, which are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseas...  
WO/2004/087643A1
Provided are a novel compound useful for a deformylase inhibitor with excellent antibacterial activity or a pharmaceutically acceptable salt thereof, a process for preparing the same, and an antibacterial composition including the same a...  
WO/2004/084842A2
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., ca...  
WO2004058683A3
Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein X, ...  
WO/2004/078144A2
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...  
WO/2004/076401A1
The invention relates to arlylcycloalkyl-substituted alkanoic acid derivatives and the physiologically acceptable salts and physiologically functional derivatives thereof. Disclosed are compounds of formula (I), wherein the radicals have...  
WO/2004/077511A2
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...  
WO/2004/076432A1
The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.  
WO2004052847A3
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...  
WO2004041211A3
One aspect of the present invention relates to urea-containing compounds. In certain embodiments, the urea-containing compounds of the present invention comprise a heteroaromatic moiety. Another aspect of the present invention relates to...  
WO2003079984A3
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...  
WO2004058145A3
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...  
WO/2004/073709A1
Compounds of formula (I) are antibacterial agents: wherein B represents R2R3N-, R2NH-C(=NR3)-, or R2NH-C(=NR3)-NR4- wherein each of R2, R3 and R4 represents hydrogen or a C1-C6 alkyl, phenyl, phenyl(C1-C6 alkyl)-, monocyclic heteroaryl, ...  
WO/2004/072020A1
This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present inventi...  
WO2004058164A3
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...  
WO/2004/069823A1
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...  
WO2004046090A3
This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are...  
WO2004056763A3
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.  
WO/2004/067499A1
A fluorinated urethane compound represented by the general formula I[-NHC(=O)O-((Rf-A1-)X1O)a-R1]m[-NHC(=O)O-((ClCH2-)X2O)b-R2] n (1) (wherein I is a group formed by removing isocyanate groups from a polyisocyanate compound; Rf is C3-21 ...  
WO/2004/067522A1
Novel azaphenylalanine derivatives of the formula I and pharmaceutically acceptable salts thereof are described wherein the substituents have the meanings as specified in the description. The compounds are useful as anticoagulants.  
WO/2004/067500A1
O-Isopropylisourea hydrogen sulfate and O-isopropyl- isourea sulfate which are represented by the general formula (I); and a process for the production thereof: (I) [wherein X is HSO4 or 1/2SO4]. O-Isopropylisourea hydrogen sulfate can b...  
WO2004046162A3
ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclo...  
WO/2004/065356A1
The invention relates to compounds of formula (I) wherein the radicals have the cited meaning, in addition to the physiologically compatible salts thereof. The compounds, for example, can be used as medicaments for preventing and treatin...  
WO/2004/064730A2
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.  
WO/2004/065351A1
Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention imp...  

Matches 601 - 650 out of 6,111